Hereditary Angioedema — designated HAE, a rare bradykinin-mediated swelling disorder with an estimated prevalence of 1 in 50,000 individuals worldwide affecting approximately 150,000 persons globally, classified into three principal types based on the genetic mechanism and C1 inhibitor activity: HAE Type I (OMIM #106100), the most common form accounting for approximately 85% of all HAE cases, caused by heterozygous loss-of-function mutations in SERPING1 (chromosome 11q12-q13.1, encoding C1 inhibitor/C1-INH, also known as C1 esterase inhibitor or serpin family G member 1, a serine protease inhibitor that is the primary regulator of the contact activation system — C1-INH forms a covalent 1:1 complex with and irreversibly inhibits activated factor XII/Hageman factor, plasma kallikrein, C1r, C1s, and factor XIa, thereby suppressing both the contact activation pathway and the classical complement pathway), resulting in reduced C1-INH protein quantity and consequently reduced plasma C1-INH functional activity (below 50% of normal), with both C4 and C1-INH antigen chronically reduced between attacks and normalizing during remission; HAE Type II (OMIM #106100, same locus), accounting for approximately 15% of SERPING1-related HAE, caused by heterozygous missense mutations in the SERPING1 reactive center loop or hinge region producing a dysfunctional C1-INH protein with preserved antigen levels but markedly reduced or absent functional activity — C4 levels are chronically low as in Type I but C1-INH antigen levels are normal or elevated; HAE with normal C1 inhibitor — formerly designated HAE Type III, comprising several genetically distinct disorders including HAE-FXII caused by gain-of-function mutations in F12 (coagulation factor XII gene, chromosome 5q35.3) that increase factor XII activation and kallikrein-kinin system activation, HAE-ANGPT1 caused by mutations in ANGPT1 (angiopoietin-1), HAE-PLG caused by gain-of-function mutations in PLG (plasminogen), and HAE-KNG1 caused by mutations in KNG1 (kininogen 1), all of which share the clinical phenotype of recurrent angioedema with normal C4 and C1-INH levels on laboratory testing, predominantly affecting women with exacerbation by estrogens (oral contraceptives, pregnancy), making clinical recognition particularly dependent on family history and careful estrogenic trigger documentation rather than standard complement laboratory testing; the fundamental pathomechanism shared across all HAE types involves dysregulated bradykinin generation — in SERPING1-related HAE Types I and II, C1-INH deficiency removes the primary brake on factor XII-mediated plasma prekallikrein activation to kallikrein, with kallikrein in turn cleaving high-molecular-weight kininogen (HMWK) to release bradykinin; in HAE-FXII, gain-of-function F12 mutations produce hyperactivatable factor XII that generates excess kallikrein and bradykinin even without precipitating trauma; bradykinin acts on B2 receptors on vascular endothelial cells to increase vascular permeability by activating endothelial eNOS, producing NO-mediated vasodilatation and tight junction disruption leading to rapid plasma extravasation into subcutaneous and submucosal tissues; clinical manifestations are attacks of recurrent, non-pitting, non-pruritic subcutaneous or submucosal swelling lasting 2-5 days without treatment, affecting the extremities (most common, causing disfiguring limb edema), genitalia, buttocks, trunk, face, tongue, pharynx and larynx (life-threatening laryngeal edema — historically the primary cause of HAE mortality with an estimated historical 20-30% lifetime mortality from asphyxiation before effective treatments were available), and gastrointestinal tract (severe abdominal attacks mimicking acute abdomen causing colicky abdominal pain, nausea, vomiting, and diarrhea from bowel wall edema, frequently leading to unnecessary laparotomy in undiagnosed patients); attacks are precipitated by identifiable triggers in approximately 50-70% of cases — trauma and surgery (dental procedures, endoscopy, intubation — always requiring pre-procedural prophylaxis), emotional stress, hormonal changes (menstruation, pregnancy, estrogen-containing contraceptives), infections, ACE inhibitors (contraindicated in HAE — ACE degrades bradykinin, and ACE inhibitor therapy dramatically worsens HAE by eliminating a critical bradykinin inactivation pathway), and physical exertion; treatment has been transformed by a generation of targeted therapies — acute attack treatment includes plasma-derived C1-INH concentrate (Berinert, Cinryze — IV bolus for moderate-severe attacks), recombinant human C1-INH (Ruconest — IV for acute attacks), icatibant (Firazyr — bradykinin B2 receptor antagonist subcutaneous injection, patient self-administered, the most widely used acute therapy), and ecallantide (Kalbitor — plasma kallikrein inhibitor SC injection, US only); long-term prophylaxis (LTP) for patients with frequent or severe attacks includes plasma-derived or recombinant C1-INH (SC or IV prophylactic dosing), lanadelumab (Takhzyro — subcutaneous anti-plasma kallikrein monoclonal antibody, every 2-4 weeks SC injection, the most effective current LTP), berotralstat (Orladeyo — oral plasma kallikrein inhibitor, daily dosing, the first oral LTP for HAE), and garadacimab (subcutaneous anti-factor XIIa monoclonal antibody, in Phase 3 trials and newly approved in some jurisdictions); emerging therapies include donidalorsen (plasma kallikrein inhibitor), garadacimab (factor XIIa inhibitor), mRNA-based SERPING1 replacement approaches, and siRNA therapies targeting KLKB1 (plasma kallikrein gene) or F12; gene therapy approaches using liver-directed AAV or mRNA delivery of C1-INH mRNA are in early clinical development.
HAE technology platforms — encompassing the HAE specialist center platforms where attack frequency and severity logging, C4/C1-INH laboratory result tracking, prophylactic therapy adherence monitoring, acute therapy availability verification, quality of life assessment, and trigger management counseling are conducted, the emergency medicine platforms where acute laryngeal attack presentations and resuscitation are managed, the specialty pharmacy and home infusion platforms managing lanadelumab self-injection supplies, berotralstat daily dosing, home C1-INH IV administration kits, and icatibant emergency self-injection kits, the obstetrics and maternal-fetal medicine platforms managing HAE attacks during pregnancy with restricted treatment options, the surgical pre-procedural prophylaxis coordination platforms ensuring C1-INH concentrate availability before all planned procedures, the laboratory platforms where serial C4 and C1-INH antigen and functional activity levels are measured, the genetic testing laboratory platforms where SERPING1 and F12 mutation analysis and family cascade testing are conducted, and the patient self-management app platforms where patients log attacks, record medication administration, and communicate with their HAE care team — must maintain the availability and performance standards required by the attack frequency and severity surveillance regularity, the prophylactic therapy adherence and efficacy monitoring intensity, the acute treatment supply chain verification continuity, the laryngeal attack emergency protocol access urgency, the surgical prophylaxis coordination precision, and the laboratory biomarker tracking frequency that define comprehensive HAE care. This guide explains why HAE care tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the attack-based episodic disease pattern, life-threatening laryngeal attack emergency management requirements, multi-drug prophylaxis management complexity, and lifelong treatment adherence monitoring obligations that characterize modern HAE management.
Why HAE Tech Platforms Require Specialized Monitoring Attention
HAE management is defined by several distinctive care coordination challenges: the laryngeal attack emergency protocol urgency — laryngeal angioedema causing upper airway obstruction is a medical emergency in HAE where death from asphyxiation can occur within minutes to hours of attack onset, and where access to acute treatment (C1-INH concentrate, icatibant, or ecallantide) must be available immediately — patients must carry their acute therapy at all times, emergency department physicians must be able to access HAE emergency protocols for patients who present without medication, and the HAE care team platform must be accessible to emergency physicians seeking urgent guidance on appropriate treatment in an unfamiliar HAE presentation; the prophylactic therapy adherence and efficacy surveillance intensity — lanadelumab SC injections every 2-4 weeks, berotralstat daily oral dosing, and prophylactic SC C1-INH twice weekly each require adherence monitoring, injection site reaction assessment, and attack frequency documentation to determine whether prophylaxis is achieving breakthrough attack rates low enough to maintain the current regimen or whether escalation or switch is required; the acute attack medication supply chain management obligation — patients on home acute therapy with icatibant self-injection kits, home C1-INH IV kits, or home lanadelumab must have uninterrupted medication supply with timely reorder processes, cold chain compliance for lanadelumab refrigerated storage, and expiration date monitoring for medications with finite shelf lives; the surgical and procedural prophylaxis coordination precision — any operative or invasive procedure (dental extraction, endoscopy, intubation, any surgery) in an HAE patient carries a risk of procedure-triggered attack that can be prevented by pre-procedural C1-INH concentrate administration, but this requires scheduling coordination between the surgical platform, the HAE care team platform, and the specialty pharmacy to ensure C1-INH concentrate is available on the day of surgery; and the pregnancy management complexity — HAE attacks typically worsen in pregnancy due to estrogen-related kallikrein-kinin system upregulation, while many standard HAE treatments are contraindicated in pregnancy (icatibant — animal data, avoid in pregnancy; tranexamic acid — avoid; danazol — absolutely contraindicated; lanadelumab and berotralstat — insufficient human safety data), making maternal-fetal medicine platform coordination and pregnancy-safe C1-INH concentrate management a specialized platform coordination obligation.
Laryngeal attack emergency protocol platforms carry the highest acute mortality risk in HAE. Untreated laryngeal angioedema can cause fatal asphyxiation within hours — emergency treatment access and protocol availability are life-critical platform capabilities that must never fail when a patient or emergency physician needs them. Monitor emergency protocol access and acute treatment documentation platforms at 1-minute intervals, 24/7.
Prophylactic therapy adherence platforms must not fail during the injection or dosing documentation windows that determine prophylaxis efficacy. Lanadelumab injection adherence, berotralstat daily dosing compliance, and prophylactic C1-INH injection timing all determine whether the patient achieves breakthrough attack rate reduction — adherence gaps create attack risk windows that could include laryngeal attacks. Monitor at 1-minute intervals during clinical and pharmacy hours.
Attack logging and frequency tracking platforms are the primary efficacy signal for prophylactic therapy. Attack frequency per month, attack location, severity, treatment required, and time to resolution are the clinical metrics that determine whether prophylaxis is effective or requires escalation. Monitor attack logging platforms at 1-minute intervals during clinical hours, with patient-accessible logging available 24/7.
Surgical prophylaxis coordination platforms must be available on the day of every planned procedure for an HAE patient. Pre-procedural C1-INH concentrate must be confirmed available and administered before the first surgical incision — a surgical prophylaxis platform failure on the day of a dental extraction or elective surgery could result in a prophylaxis gap and a peri-operative HAE attack in a setting that is particularly dangerous. Monitor at 1-minute intervals during surgical coordination hours.
What to Monitor on an HAE Tech Platform
Genetic Testing — SERPING1 and F12 Mutation Analysis
Monitor SERPING1 mutation analysis records (sequencing of all 8 SERPING1 coding exons and splice sites — mutation spectrum includes nonsense, frameshift, missense, and large deletion/duplication mutations across the gene; missense mutations in the reactive center loop at P1-P1' position produce dysfunctional protein — basis of Type II HAE; MLPA or CNV analysis for intragenic deletions/duplications not detectable by standard sequencing), F12 mutation analysis records (gain-of-function mutations in F12 Exon 9 — c.983C>A encoding p.Thr328Lys and c.983_984del encoding p.Thr328_Ile329del are the most common HAE-FXII variants; less common F12 mutations at other positions; HAE-FXII predominantly affects women with estrogen exposure and may be clinically silent in men), ANGPT1, PLG, and KNG1 mutation records (rare HAE subtypes — sequencing for patients with recurrent angioedema, normal C4 and C1-INH, no SERPING1 or F12 mutation, and family history or estrogen exacerbation), genetic counseling records (autosomal dominant inheritance for SERPING1-related HAE with high penetrance and variable expressivity; 50% risk to offspring; family cascade testing referral records), and variant interpretation records (SERPING1 VUS — functional C1-INH activity assay data to resolve pathogenicity classification) at 1-minute intervals during laboratory hours.
C4, C1-INH Antigen, and C1-INH Functional Activity Laboratory Monitoring
Monitor C4 records (complement component 4 — the most sensitive screening test for C1-INH deficiency; C4 is chronically reduced in HAE Types I and II between attacks due to ongoing complement consumption from unregulated C1r/s activation; C4 normalization during quiescent periods is uncommon, making a normal C4 in a symptomatic patient a strong argument against C1-INH deficiency; monitoring C4 during prophylactic C1-INH therapy as a pharmacodynamic biomarker of C1-INH replacement adequacy), C1-INH antigen records (C1 inhibitor antigen level by immunoassay — reduced in HAE Type I, normal or elevated in HAE Type II), C1-INH functional activity records (chromogenic or ELISA C1-INH function assay — below 50% of normal in both HAE Types I and II; functional activity is the diagnostic gold standard and the primary laboratory monitor for adequacy of C1-INH replacement therapy), and follow-up laboratory monitoring records (C4 and C1-INH functional activity at 6-12 month intervals in stable patients; C4 trend during prophylactic C1-INH therapy as pharmacodynamic endpoint) at 1-minute intervals during laboratory hours.
Attack Frequency and Severity Logging
Monitor attack log records (prospective attack diary — attack date, onset time, body site affected, attack duration, severity scale 1-10, breakthrough on prophylaxis, precipitating trigger, acute treatment used and time to administration, time to symptom relief, healthcare utilization — ED visit or hospitalization), attack frequency metrics (attacks per month, attacks per year — baseline pre-treatment attack rate; post-prophylaxis attack frequency; percent reduction from baseline — HAE-1/2 patients average 1-5 attacks per month without prophylaxis, with acceptable prophylaxis response defined as ≥50% reduction in attack rate), attack location records (extremity, abdomen, face, genitalia, laryngeal — laryngeal attack rate is the primary safety metric; any breakthrough laryngeal attack on prophylaxis triggers urgent prophylaxis escalation consideration), attack severity records (number requiring acute treatment; number requiring ED visit or hospitalization; number resulting in laryngeal attack emergency), and patient-reported outcome records (Angioedema Quality of Life questionnaire — AE-QoL; HAE patient global impression scales; validated HAE-specific QoL instruments) at 1-minute intervals during clinical hours, with 24/7 patient access for self-logging between clinic visits. Alert immediately — attack logging platform failures that prevent a patient from documenting a series of attacks over a 2-week period — including two abdominal attacks and one laryngeal attack that resolved after icatibant self-injection — mean that the HAE physician reviewing the patient's prophylaxis efficacy at the next scheduled clinic visit will be unable to identify the breakthrough laryngeal attack that mandates prophylaxis escalation.
Prophylactic Therapy Management
Monitor lanadelumab records (Takhzyro — SC injection 300 mg every 2 weeks or 300 mg every 4 weeks in well-controlled patients; injection site reactions; attack rate response at 12-week assessment; anti-drug antibody testing at appropriate intervals; cold chain compliance — refrigerated storage at 2-8°C; supply reorder scheduling at 4-6 week intervals), berotralstat records (Orladeyo — 150 mg oral once daily; GI tolerability, particularly nausea and abdominal pain; drug-drug interaction documentation — berotralstat is a P-gp inhibitor and sensitive CYP2D6 inhibitor; attack rate response at 12-week assessment), prophylactic C1-INH records (subcutaneous HAEGARDA 60 IU/kg every 3-4 days at home or Ruconest IV prophylaxis — injection records, site rotation, cold chain compliance, supply reorder), tranexamic acid records (antifibrinolytic LTP for mild disease — contraindicated in thromboembolic disease; LFT monitoring, ophthalmologic monitoring for retinal changes with long-term use; reduced use since advent of targeted therapies), danazol records (attenuated androgen — hepatotoxicity risk requiring 6-monthly LFT; virilization side effects; contraindicated in pregnancy, children, liver disease; largely replaced by targeted therapies but some patients maintained on low-dose danazol; danazol discontinuation records when switching to targeted therapy), and prophylaxis switch or escalation records (suboptimal response definition — breakthrough attacks requiring acute treatment; escalation or switch decision documentation) at 1-minute intervals during clinical and pharmacy hours.
Acute Attack Treatment and Self-Administration Management
Monitor acute treatment supply records (icatibant home self-injection kit — 30 mg SC per attack; supply at home, at work, and as travel kit; expiry date monitoring; repeat dose records for attacks not responding to first injection within 6 hours; temperature storage compliance), home C1-INH IV kit records (plasma-derived Berinert 20 IU/kg IV or Cinryze — home infusion kit, nurse training records, vein access assessment, IV pole and pump records, cold chain compliance), ecallantide records (Kalbitor — SC injection 30 mg, US only, must be administered by healthcare provider due to anaphylaxis risk — outpatient infusion clinic administration records), recombinant C1-INH records (Ruconest — IV administration records for acute moderate-severe attacks in outpatient or emergency settings), and patient self-administration training records (training completion, competency assessment, refresher training schedule — patient must demonstrate correct icatibant injection technique and recognize laryngeal attack symptoms before home supply authorization) at 1-minute intervals during clinical and pharmacy hours.
Laryngeal Attack Emergency Protocol Management
Monitor laryngeal attack emergency protocol records (emergency protocol documentation — symptom recognition criteria for laryngeal involvement, immediate acute treatment administration instructions, emergency services activation guidance, ED transfer criteria, return precautions after treatment), emergency department protocol access records (HAE emergency management protocol available to ED clinical staff — C1-INH or icatibant first-line; airway management backup plan; intubation records only as last resort after acute HAE treatment fails), emergency acute treatment records for ED visits (treatment given, time from arrival to treatment, response, intubation required, ICU admission, hospital length of stay), and patient-carried emergency card records (wallet card and digital document with diagnosis, emergency treatment protocol, and HAE physician contact details — issued and updated at each clinic visit) at 1-minute intervals, 24/7. Alert immediately — laryngeal attack emergency protocol platform failures at any hour of the day or night that prevent an emergency physician from accessing the HAE management protocol when a patient without their medication presents to the ED with rapidly progressive throat tightening and muffled voice create a platform-mediated risk of inappropriate airway management in a potentially reversible HAE laryngeal attack.
Surgical and Procedural Prophylaxis Coordination
Monitor pre-procedural prophylaxis records (planned procedure date and type — dental, endoscopy, surgery; HAE prophylaxis protocol: IV C1-INH concentrate (Berinert or Cinryze) 20 IU/kg within 6 hours before procedure onset; prophylaxis confirmation from surgical team and pharmacy on day of procedure), emergency surgery C1-INH records (C1-INH concentrate held by surgical team for emergency intubation, urgent GI endoscopy, or emergency surgery in HAE patients — availability confirmation records), post-procedural monitoring records (4-24 hours post-procedure attack monitoring — procedures are a high-risk HAE trigger period; post-operative attack management if prophylaxis is ineffective or wears off), and obstetric procedural records (C-section, epidural, or instrumental delivery in pregnant HAE patients — delivery suite C1-INH availability records, obstetric anesthesia briefing records) at 1-minute intervals during surgical coordination hours.
Pregnancy and Contraception Management in HAE
Monitor pregnancy management records (HAE attack frequency change in pregnancy — typically increases due to estrogen; C1-INH concentrate (plasma-derived) as the only safe acute HAE treatment in pregnancy; icatibant — avoid in pregnancy; lanadelumab and berotralstat — insufficient data, avoid; danazol — absolutely contraindicated in pregnancy), contraception records (estrogen-containing combined oral contraceptives — contraindicated in HAE, trigger or worsen attacks; progestogen-only pill or non-hormonal contraception recommended; IUD, barrier method records), and maternal-fetal medicine coordination records (high-risk obstetrics consultation records; delivery plan with C1-INH concentrate availability; postpartum monitoring — HAE may worsen in the postpartum period) at 1-minute intervals during obstetric and clinical hours.
Trigger Avoidance and Quality of Life Management
Monitor trigger identification records (identified triggers from attack log analysis — stress, dental procedures, ACE inhibitors, estrogen, infections, physical trauma; trigger diary records; trigger avoidance counseling documentation), ACE inhibitor contraindication records (ABSOLUTELY contraindicated in all HAE patients — ACE inhibitor prescription check records; pharmacy alert records for ACE inhibitor prescription attempts in HAE-diagnosed patients; ARB as safe antihypertensive alternative), and quality of life assessment records (AE-QoL scores at 6-12 month intervals; correlation of QoL improvement with attack rate reduction on prophylaxis; work productivity loss assessment — HAE attacks cause significant occupational productivity loss; school attendance records for pediatric HAE patients) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. HAE management coordinates across HAE specialist centers (attack logging, prophylaxis management, and treatment escalation), emergency medicine (laryngeal attack emergency management), specialty pharmacy and home infusion (lanadelumab, berotralstat, home C1-INH supply), surgical and procedural teams (pre-procedural C1-INH prophylaxis), obstetrics and maternal-fetal medicine (pregnancy management), genetic testing and counseling (SERPING1/F12 mutation analysis and cascade testing), pediatric allergy/immunology (pediatric HAE management — attacks can begin in childhood), immunology and allergy (HAE diagnosis and complement testing), and hematology (coagulation factor evaluation in HAE-FXII) — authentication failures across this multi-specialty coordination infrastructure disrupt the continuous attack prevention and emergency management program that HAE requires across all hours of the day.
SSL Certificates
Monitor SSL certificate expiry across all HAE specialist center platforms, attack logging mobile and web apps, emergency protocol portals, specialty pharmacy platforms, surgical coordination systems, genetic testing portals, and maternal-fetal medicine platforms. Certificate errors that make patient attack logging apps unavailable or emergency protocol portals inaccessible represent high-stakes failures in a disease where 24/7 self-management capability is a clinical safety requirement.
HIPAA and Genetic Information Privacy Considerations
HAE technology platforms handle GINA-protected genetic information (SERPING1 and F12 mutation results with autosomal dominant inheritance implications for children and siblings), longitudinal attack diary records documenting the frequency and anatomic distribution of HAE attacks (which have significant disability and life insurance implications), laryngeal attack emergency records including intubation and ICU admissions, complement laboratory records, pregnancy management records combining obstetric and rare disease records in a single platform stream, and prescription records for controlled medications (danazol — a Schedule III androgen; tranexamic acid with thromboembolic risk implications). The attack log data — including timestamps and locations of attacks — combined with trigger documentation may contain highly sensitive personal and behavioral information (stress events, workplace conflicts, reproductive decisions) that requires stringent access controls beyond standard HIPAA minimum necessary principles.
HAE patient registries (US HAEA registry; European HAE patient registry — HAE International; Icatibant Outcome Survey; HELP OLE long-term lanadelumab extension) hold longitudinal attack frequency, treatment response, and quality-of-life outcome data requiring IRB oversight, DUA agreements, HIPAA-compliant de-identification, and GDPR compliance for European registry participants. Pediatric HAE records require parental consent with patient assent transition at the age of majority.
Alerting Strategy for HAE Tech Platforms
Immediate 24/7 alerting for laryngeal attack emergency protocol access: Laryngeal angioedema is a potentially fatal emergency — the emergency protocol platform must be accessible at every hour without exception.
Immediate 24/7 alerting for patient attack logging platforms: Patients need to log attacks immediately when they begin — including at 3 AM during a laryngeal attack — and the logging record creates the time-stamped evidence of treatment administration that is clinically critical.
Immediate clinical-hours alerting for prophylactic therapy supply chain and adherence platforms: Lanadelumab cold chain failures, berotralstat reorder delays, and prophylactic C1-INH supply disruptions create attack risk windows that may include laryngeal attacks.
Immediate surgical-hours alerting for surgical prophylaxis coordination platforms: Pre-procedural C1-INH prophylaxis must be confirmed available before the first procedure begins — a surgical prophylaxis platform failure on the morning of a scheduled procedure is an acute clinical safety issue.
Immediate clinical-hours alerting for C4/C1-INH laboratory biomarker platforms: Pharmacodynamic C4 and C1-INH activity results drive prophylaxis adequacy assessments and therapy switch decisions.
Immediate clinical-hours alerting for attack frequency and severity tracking platforms: Breakthrough laryngeal attack logging triggers urgent prophylaxis escalation — delayed attack log delivery to the clinical team delays the escalation decision.
Sustained-failure alert (10–15 minutes): Trigger avoidance counseling records, QoL assessment platforms, danazol/tranexamic acid monitoring records.
30-day advance warning: SSL certificates across all domains.
Status Page for HAE Care Team Communication
A real-time status page gives HAE specialists managing attack logs and prophylaxis escalation, emergency physicians accessing acute attack treatment protocols, specialty pharmacists managing lanadelumab cold chain and supply reorder, surgical teams coordinating pre-procedural C1-INH prophylaxis, obstetricians and maternal-fetal medicine specialists managing pregnancy, genetic counselors coordinating SERPING1 family cascade testing, pediatric allergists managing childhood-onset HAE, home infusion nurses managing C1-INH home therapy, and immunologists interpreting C4/C1-INH laboratory results immediate platform visibility without inbound IT support contact.
Include the status page URL in laryngeal attack emergency management protocols, surgical pre-procedural prophylaxis backup procedures, and patient self-management emergency contact information.
Vigilmon Setup for HAE Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | SERPING1 / F12 genetic testing | 1 min | Slack + PagerDuty (lab hours) | | C4 complement (biomarker) | 1 min | Slack + PagerDuty (lab hours) | | C1-INH antigen and functional activity | 1 min | Slack + PagerDuty (lab hours) | | Attack frequency and severity logging (patient portal) | 1 min | Slack + PagerDuty (24/7) | | Laryngeal attack emergency protocol access | 1 min | Slack + PagerDuty (24/7) | | Lanadelumab cold chain and supply management | 1 min | Slack + PagerDuty (pharmacy hours) | | Berotralstat daily adherence and tolerability | 1 min | Slack + PagerDuty (clinical hours) | | Prophylactic C1-INH home infusion supply | 1 min | Slack + PagerDuty (clinical hours) | | Icatibant home self-injection kit supply and expiry | 1 min | Slack + PagerDuty (clinical hours) | | Home C1-INH IV kit supply and expiry | 1 min | Slack + PagerDuty (clinical hours) | | Acute treatment self-administration training records | 1 min | Slack + PagerDuty (clinical hours) | | Surgical and procedural prophylaxis coordination | 1 min | Slack + PagerDuty (surgical hours) | | Obstetric and pregnancy management records | 1 min | Slack + PagerDuty (clinical hours) | | ACE inhibitor contraindication pharmacy alert | 1 min | Slack + PagerDuty (pharmacy hours) | | Trigger documentation and avoidance counseling | 2 min | Slack (clinical hours) | | Quality of life (AE-QoL) assessment records | 2 min | Slack (clinical hours) | | Genetic counseling and family cascade testing | 2 min | Slack (business hours) | | Danazol/tranexamic acid monitoring records | 2 min | Slack (clinical hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure SERPING1 and F12 genetic testing platforms with immediate laboratory-hours alerting
- Add C4 complement biomarker reporting with immediate laboratory-hours alerting
- Configure C1-INH antigen and functional activity laboratory reporting with immediate laboratory-hours alerting
- Add patient attack frequency and severity logging portals with 24/7 immediate alerting — patients need to log attacks at any hour, including during active laryngeal attacks
- Configure laryngeal attack emergency protocol access with 24/7 immediate alerting — this is the highest-acuity emergency monitoring workflow in HAE
- Add lanadelumab cold chain integrity and supply management platforms with immediate pharmacy-hours alerting
- Configure berotralstat daily adherence and GI tolerability tracking with immediate clinical-hours alerting
- Add prophylactic C1-INH home infusion supply chain platforms with immediate clinical-hours alerting
- Configure icatibant home self-injection kit supply and expiry monitoring with immediate clinical-hours alerting
- Add home C1-INH IV kit supply and expiry monitoring with immediate clinical-hours alerting
- Configure acute treatment self-administration training record platforms with immediate clinical-hours alerting
- Add surgical and procedural prophylaxis coordination platforms with immediate surgical-hours alerting — pre-procedural C1-INH must be confirmed available before every planned procedure
- Configure obstetric and pregnancy management platforms with immediate clinical-hours alerting
- Add ACE inhibitor contraindication pharmacy alert systems with immediate pharmacy-hours alerting
- Configure trigger documentation and avoidance counseling platforms with sustained-failure alerting
- Add quality of life and AE-QoL assessment platforms with sustained-failure alerting
- Configure genetic counseling and family cascade testing coordination platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all HAE specialist center, attack logging, emergency protocol, specialty pharmacy, genetics, surgical coordination, and obstetric platforms with 30-day advance email warning
Conclusion
HAE technology platforms are embedded in clinical decisions where laryngeal attack emergency protocol platform availability at 2:17 AM when a 34-year-old woman with known HAE Type I wakes with the distinctive sensation of progressive throat tightening and muffled voice that she recognizes from prior laryngeal attacks — and reaches for the icatibant auto-injector she keeps on her nightstand but discovers the kit she retrieved from the pharmacy last week was inadvertently stored at room temperature for 72 hours during a cold chain interruption and has been flagged as potentially compromised by the specialty pharmacy monitoring system — and her husband calls 911 while she opens the HAE emergency information app on her phone to generate the emergency protocol PDF for the responding paramedics and the ED physician who has never seen an HAE patient and needs to know immediately that epinephrine is ineffective for bradykinin-mediated angioedema and that C1-INH concentrate or icatibant from the hospital's emergency pharmacy supply must be located within minutes — and the emergency protocol app must be accessible, loading the correct treatment protocol without delay at 2:17 AM even though it is accessed by fewer than 200 users globally per night — cannot be disrupted by emergency protocol platform failures that return a 503 error when the ED physician at a community hospital 40 miles from the nearest HAE center attempts to access the management protocol for a patient whose stridor is audible across the room; where prophylaxis supply chain platform availability on the Friday afternoon before a long weekend when the HAE specialty pharmacy coordinator is processing the lanadelumab refill request for a 47-year-old man with HAE Type II who is due for his every-4-week SC injection on Monday morning — and the specialty pharmacy platform must confirm insurance authorization, generate the shipping order with the cold pack for weekend delivery, and create the delivery tracking record that the patient can use to verify that the vial arrives at his home by Sunday evening with the temperature monitoring indicator confirming cold chain integrity throughout transit — cannot be disrupted by pharmacy platform failures that leave the refill request unprocessed until after the Friday close of business, creating a scenario where the patient either delays his Monday injection by 3-5 days (creating a prophylaxis gap during which his kallikrein-kinin system is inadequately suppressed) or presents to an urgent care clinic seeking emergency IV C1-INH to cover the prophylaxis gap; and where surgical prophylaxis coordination platform availability at 7:45 AM on the day of a 58-year-old woman's scheduled right total knee replacement — an HAE Type I patient who has been in her surgeon's office twice in the past 2 months completing pre-operative clearance, and whose HAE management plan calls for 1,500 units of Berinert IV within 6 hours before the first surgical incision — cannot be disrupted by hospital pharmacy dispensing system failures that cannot locate the pre-ordered Berinert in the morning queue at 7:45 AM when the anesthesiologist needs to administer prophylaxis 45 minutes before her 8:30 AM OR time, creating the choice between delaying the surgical start until the Berinert can be located and administered or proceeding without prophylaxis and accepting the risk of a peri-operative HAE attack in a patient under general anesthesia and intubated. A laryngeal attack emergency protocol platform that is unavailable when an ED physician needs it at 2 AM for a patient in evolving airway compromise, a prophylaxis supply chain platform that leaves a refill unprocessed until after close of business on a holiday weekend, a surgical prophylaxis coordination system that cannot locate the pre-ordered C1-INH at 7:45 AM on the morning of the patient's knee replacement — these are not IT incidents. They are clinical disruptions in the management of a rare but potentially fatal bradykinin-mediated swelling disorder where the emergency protocol access window, the prophylaxis supply chain continuity, and the pre-procedural prophylaxis confirmation are all measured in hours, and where platform failures at precisely the moments when these systems must function — the 2 AM airway emergency, the Friday afternoon refill processing, the 7:45 AM pharmacy dispensing confirmation — can mean the difference between a managed HAE event and a catastrophic outcome.
Uptime monitoring gives HAE tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to HAE specialists managing attack frequency and prophylaxis escalation, emergency physicians seeking acute attack management protocols, specialty pharmacists managing lanadelumab cold chain and supply chain continuity, surgical teams confirming pre-procedural C1-INH availability, obstetricians managing pregnancy-associated HAE attacks, genetic counselors coordinating SERPING1 family cascade testing, and home infusion nurses maintaining C1-INH self-administration programs that platform operational reliability matches the laryngeal attack emergency urgency, prophylaxis supply chain continuity requirements, surgical prophylaxis coordination precision, and lifelong attack prevention monitoring obligations of modern HAE management.
Start monitoring your HAE care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #HAE #hereditaryAngioedema #SERPING1 #C1inhibitor #C1INH #F12 #bradykinin #icatibant #lanadelumab #berotralstat #angioedema #laryngealEdema #angiopoietin #kallikrein #C4complement #contactActivation #Berinert #Takhzyro #Orladeyo #GINA #HIPAA #healthtech #digitalhealth #uptime #sre